Table 2.
Treatment patterns after initiation of aripiprazole lauroxil (AL)
| Recent antipsychotic use | All patients N = 485 |
||||
|---|---|---|---|---|---|
| Recent LAI N = 217 |
Recent oral N = 195 |
None N = 73 |
P value | ||
| Initial AL dosage strength givena, n (%) | < 0.001 | ||||
| 441 mg | 19 (8.8) | 51 (26.2) | 8 (11.0) | 78 (16.1) | |
| 662 mg | 93 (42.9) | 57 (29.2) | 24 (32.9) | 174 (35.9) | |
| 882 mgb | 105 (48.4) | 87 (44.6) | 41 (56.2) | 233 (48.0) | |
| PDC, mean (SD) | 0.79 (0.29) | 0.72 (0.32) | 0.74 (0.33) | 0.039 | 0.76 (0.31) |
| Number of doses during follow-up, mean (SD) | 5.0 (2.1) | 4.3 (2.1) | 4.3 (2.2) | 0.001 | 4.6 (2.1) |
| Proportion of patients receiving ≥ 6 doses of AL | 116 (53.5) | 72 (36.9) | 23 (31.5) | < 0.001 | 211 (43.5) |
| Duration of AL exposure in days, mean (SD) | 143.0 (53.0) | 129.0 (58.4) | 133.6 (60.2) | 0.039 | 136.0 (56.6) |
| Proportion of patients who discontinued, n (%) | 63 (29.0) | 78 (40.0) | 24 (32.9) | 0.062 | 165 (34.0) |
| Time to first discontinuation in days, mean (SD)c | 58.1 (30.0) | 57.9 (33.2) | 44.9 (25.9) | 0.164 | 56.1 (31.2) |
Statistically significant values are in bold
LAI long-acting injectable, PDC proportion of days covered, SD standard deviation
aNo patients initiated at a dose of 1064 mg as it was not yet approved during the years in which the analysis was conducted
bThe 882-mg dose was assumed to be the 4-week dose for all patients
cAmong patients who discontinued AL (n = 134)